Epidemiological studies point to sexual dimorphism as a relevant factor for cancer incidence and survival. Overall, females have a lesser risk and better prognosis than males in a wide range of cancer types that are unrelated to reproductive function, such as cancers of the colon, skin, head and neck, oesophagus, lung and liver
A notable exception in which incidence is higher in women is thyroid cancer 3 . Importantly, this trend is independent of the ethnicity of the studied population 4 . The generally higher cancer risk in the male population was previously attributed to diet, environmental exposure to chemicals or carcinogens and risk behaviours such as smoking and alcohol consumption. However, even after appropriate adjustment for these risk factors and statistical evaluation of the data, adult females still have more overall cancer protection than males 5, 6 , with substantial sex differences also existing in some childhood malignancies, specifically T cell acute lymphoblastic leukaemia (T-ALL) and hepatoblastoma 7 . This Opinion article investigates the possible cellular and molecular basis of differences between the two sexes in susceptibility to cancer in non-reproductive tissues, focusing on the complex effect that sex hormones and sex chromosomes can have in this context. of other tissues, such as breast, prostate, colon, skin, endometrial and brain tissue, even though in these cases autocrine GH production by cancer cells may be more important than pituitary secretion 15 .
Relative to protein hormones, much more abundant information exists on the effect of sex steroid hormones on cancer development in non-reproductive organs. These hormones, being lipid soluble, can enter the plasma membrane of target cells and interact directly with intracellular receptors that can shuttle to the nucleus to affect gene expression 16 .
The action of these hormones extends, at the epigenetic level, to DNA methylation and chromatin conformation 17, 18 . Analysis of gene expression in different non-reproductive tissues indicates the existence of a gender-specific influence on transcription 19, 20 , which is paralleled at the level of chromatin organization 21 . As discussed below, sex hormone signalling pathways are likely to affect cancer susceptibility through multiple intrinsic and extrinsic mechanisms, affecting cancer stem cell self-renewal, the tumour micro environment, the immune system and the overall metabolic balance of an organism. The vast majority of accrued information relates to three major sex steroid hormone receptors -oestrogen receptor-α (ERα), ERβ and androgen receptor (AR) -on which we focus (FIG. 2) . It is important to note, however, that the progesterone receptor, which is under intense investigation in breast cancer 22 , may also be involved in cancer of nonreproductive organs, as recently reported for non-small-cell lung cancer (NSCLC) 23 and colon cancer 24 .
Stem cell self-renewal. Specific ablation of ERα, ERβ and AR affects the homeostasis and/or regeneration of organs that are unrelated to reproductive functions, such as lungs 25 , colon 26 and skin [27] [28] [29] . Sex steroids have an effect on stem cell populations of various types. Oestrogens enhance self-renewal of embryonic stem cells 30 , increase endothelial progenitor cell numbers 31, 32 and, during pregnancy, contribute to the expansion of haematopoietic stem cell (HSC) populations 33 . Neural stem Importantly, a substantial interplay is likely to exist between the two, and understanding this could improve cancer prevention and therapy.
Sex-related hormone signalling
Both steroid and protein hormones are involved in sexual development and reproductive functions. Gonadal steroids control the production of protein hormones through the hypothalamic-pituitary axis, starting around birth but having a more pronounced effect in puberty and adulthood. Sex-related protein hormones, such as prolactin (PRL), luteinizing hormone (LH), follicle-stimulating hormone (FSH) and gonadotropin-releasing hormone (GNRH), are mainly implicated in cancer of reproductive tissues, such as prostate, ovarian and breast tissue [8] [9] [10] . However, as detailed further below, PRL also impinges on cancer development in non-reproductive organs, specifically the liver 11, 12 . Similar to other protein hormones with a broader function, growth hormone (GH) has been implicated in liver cancer 13 . GH affects liver gene expression differentially in the two genders, possibly because it undergoes pulsatile secretion into the plasma in men and constant secretion in women 14 . Besides its action in the liver, GH has been implicated in tumorigenesis Abstract | The incidence of many types of cancer arising in organs with nonreproductive functions is significantly higher in male populations than in female populations, with associated differences in survival. Occupational and/or behavioural factors are well-known underlying determinants. However, cellular and molecular differences between the two sexes are also likely to be important. In this Opinion article, we focus on the complex interplay that sex hormones and sex chromosomes can have in intrinsic control of cancer-initiating cell populations, the tumour microenvironment and systemic determinants of cancer development, such as the immune system and metabolism. A better appreciation of these differences between the two sexes could be of substantial value for cancer prevention as well as treatment. cell proliferation has been reported to fluctuate during the oestrous cycle, and exogenous oestrogen administration is sufficient to increase neural stem cell division 34 . 17β-oestradiol, the most potent form of oestrogen, can also counteract senescence: through ERα activation it can promote telomerase expression or induce the E3 ligase MDM2, thus indirectly suppressing p53 (REFS 35, 36) .
Similar to oestrogens, androgens are involved in the control of HSC self-renewal. Ageing men experience a reduction in androgen production and are prone to develop normocytic anaemia, a condition characterized by a reduced number of red blood cells, which can be corrected with androgen supplementation 37 . Androgen supplementation also reduces acquired aplastic anaemia, characterized by a reduced production of all blood cells, and dyskeratosis congenita, a genetic syndrome classically associated with nail dystrophy, skin pigmentation and oral leukoplakia 38, 39 . These two diseases result in telomere disfunction and bone marrow failure owing to impairment of HSCs and are linked to cancer development. Molecularly, in primary HSCs, androgens induce telomerase expression through aromatase-dependent conversion of testosterone into oestrogen and ERα activation 40 .
The role of ERα signalling in breastcancer-initiating cells is an area of active investigation 41, 42 , and so is the role of AR in prostate cancer 43, 44 , but the role of ERα and AR in the self-renewal of initiating cancer cells of other tumour types is an important possibility that remains to be addressed experimentally. In this context, we note that disruption of the gene encoding ERβ (Esr2) in mice promotes hyperplastic expansion of leukocytes resembling chronic myeloid leukaemia (CML) 45 , a haematological disorder that results from HSC transformation 46 . Interestingly, CML survival is higher in women than men 47 , and it has been suggested that CML may be sensitive to pharmacological ERβ activation 45 .
Cancer stroma. Various components of the tumour microenvironment are under sex hormone control. The effect of sex hormones on the behaviour of stromal fibroblasts is not well understood. Cancerassociated fibroblasts (CAFs) are persistently activated fibroblasts that share properties with fibroblasts at wound sites 48 . Although well-known differences exist in skin wound healing between the two sexes 27, 28 , and
Oestrogens have been shown to promote mobilization of bone marrow-derived precursors to breast cancer stroma 52 and increase stromal density 53 . In cervical cancer, ERα expression in stromal fibroblasts is fibroblasts exert an important role in the first phases of the process, studies on the effect of sex hormones on CAFs function have mostly focused on prostate [49] [50] [51] , breast 52, 53 and cervical 54 cancer. 49 . This beneficial role contrasts with additional observations that implicate ERα activity as a positive regulator this receptor in fibroblasts promotes initial stages of the disease 50 , clinical evidence points to the opposite possibility -that sustained AR expression in cancer stroma is linked to less-aggressive cancer and better prognosis 51 . Angiogenesis is another key determinant of cancer development. Oestrogens are pro-angiogenic and enhance endothelial cell proliferation and migration, which is most well established in the endometrium during the female reproductive cycle 32, 57 . This is mediated by diffusible factors such as platelet-activating factor (PAF) 58 and vascular endothelial growth factor A (VEGFA) 59 , which are frequently secreted by cancer cells in response to oestrogens. In contrast to ERα, ERβ activation in neoplastic breast cells negatively affects blood vessel formation 60 . Androgens also stimulate endothelial cell migration and new blood vessel formation through VEGFA, but this effect is only seen in male endothelial cells, owing to their higher levels of AR expression 61 . The roles that ER and AR signalling have in the stromal compartment of tumours of non-reproductive systems are likely to be important, and their translational potential should be explored. More specifically, the fact that, in endothelial cells, AR can directly associate with and stimulate VEGF receptor 2 (VEGFR2) activity 62 and promote proliferation 63 suggests that AR antagonists could be beneficial against tumour angiogenesis. Such antagonists may be especially effective at normalizing aberrant vascularization in advanced liver cancer, a malignancy under the positive control of androgens (discussed below). The effect of selective modulators of ER activity such as tamoxifen on various components of cancer stroma will have to be similarly evaluated.
Inflammation and the immune system.
The microenvironment encompasses different leukocyte populations, with macrophage M1 polarization playing a key part in chronic inflammation-associated cancer development 64 . ERα significantly reduces the pro-inflammatory activity 65 and tumour-promoting properties 66 of macrophages. By contrast, AR promotes macrophage release of pro-inflammatory cytokines during wound healing 29 and is required for cytokine production by these cells in prostate tumorigenesis 67 .
Other cells of the myeloid and lymphoid lineages, such as neutrophils or lymphocytes, also express ERs and ARs, and sex hormones can modulate the immune system at of prostate epithelial cells 55 , suggesting that this receptor functions differently in the two compartments. In contrast to ERα, ERβ activation has been reported to restrain prostate hyperplasia and cancer by inducing death of both epithelial and stromal cells 56 . Conflicting results exist concerning the role of AR signalling in prostate CAFs. Whereas animal model studies indicate that Figure 2 | Role of sex steroid hormone receptors in non-reproductive tissues. Summary of the complexity of biological functions of the three sex steroid hormone receptors in non-reproductive tissues. The activation of oestrogen receptor-α (ERα) elicits haematopoietic stem cell (HSC) expansion and mobilization, favours skin wound healing, promotes blood vessel formation and endothelial cell precursor mobilization, reduces hepatocyte proliferation and restrains the inflammatory role of macro phages. ERβ also blocks macrophage activation and, contrary to ERα, negatively regulates angio genesis. ERβ promotes differentiation and suppresses tumour formation in several organs, such as the skin (acting on both keratinocytes and melanocytes), and is required for the proper morphogenesis of the lung and colon. Androgen receptor (AR) suppresses wound healing and promotes angiogenesis, liver cell proliferation and macrophage activation through the stimulation of tumour necrosis factor (TNF) and CC-chemokine ligand 4 (CCL4). Activity of androgenic hormones is not limited to AR activation; through the action of aromatase, such hormones are converted into oestrogens, thus indirectly controlling pathways affected by ERα.
multiple levels through control of immunemodulatory cytokines 68 . Interestingly, AR activity promotes neutrophil production and restrains T cell proliferation 69 . This can be of relevance for cancer, as a higher neutrophil/lymphocyte ratio is considered to be a poor prognostic biomarker in several types of tumour 70 . Pathogenesis of autoimmune diseases, to which females are more susceptible than males 71 , is linked to increased cytotoxic T cell function and dampening of suppressor (CD4 + CD25 + ) regulatory T cells (T Reg cells), a subpopulation of T cell that promotes self-tolerance and restrains cancer immune surveillance 72 . The forkhead box protein P3 (FOXP3) transcription factor is a master regulator of T Reg cell number and function 73 , and the FOXP3 gene is X-linked. Polymorphisms and mutations in FOXP3 result in reduced T Reg cell functionality 74 and are associated with a rare syndrome that affects young boys, known as IPEX (immuno dysregulation, polyendocrin opathy and enteropathy, X-linked syndrome) 75 . The size of a T Reg cell population positively correlates with the levels of 17β-oestradiol 68 , which induces both T Reg cell expansion and FOXP3 expression 76 .
Testosterone stimulation also increases the number of T Reg cells both in vivo and in vitro, through a mechanism that involves AR recruitment to the FOXP3 locus and enhanced FOXP3 expression 77 . Besides being positively regulated by both oestrogens and androgens, FOXP3 expression and function are under combined control of multiple cytokines 73 -such as interleukin-6 (IL-6) and IL-1-that promote degradation of the FOXP3 protein and therefore suppress T Reg cell populations 78 in a complex manner that extends beyond gender.
Besides a differential effect on various immune cell populations, sex hormones can also affect the immune system indirectly, through the gut microbiome. The composition of gut bacterial populations can underlie a greater female susceptibility to autoimmune diabetes 79, 80 , and, in males, changes in bacterial commensal populations mediate the protective effects of testosterone rise after puberty 81 . Besides its effect on the immune system, gut microbiota composition can affect tumour development through a variety of other mechanisms and can influence the efficacy and toxicity of chemotherapy 82 , the latter of which is greater in the female population 83, 84 . The X chromosome is also highly enriched in immune-related genes 68 , and there are several X-linked microRNAs (mi RNAs) Selective androgen modulators that activate AR mainly in the muscle have been tested for their ability to revert or compensate for body-mass wasting, and one of these AR modulators has led to improvement of lean body mass and physical condition 97 .
Hormones in non-reproductive cancers A clear example of greater cancer susceptibility of the male versus female populations owing to hormonal sex influences is represented by hepatocellular carcinoma (HCC), which occurs more frequently in men 1, 2 . A detailed analysis indicates that AR and ERα contribute to hepatocarcinogenesis in an antagonistic manner through differential regulation of gene expression (FIG. 3) : AR stimulates, whereas ERα restrains, proliferation and metabolism of nucleotides and amino acids 98 . This difference is dependent on FOXA1 and FOXA2 pioneer factors, which are required for chromatin recruitment of nuclear receptors. Ablation of FOXA proteins eliminates gender differences, converting the tumour-suppressive role of oestrogen into a tumour-promoting one 98 . Previous evidence indicates that oestrogens exert a protective function in HCC by reducing the production of inflammatory mediators such as IL-6 (REF. 99 ), which has also been reported to be a target of FOXA pioneer factors 100 . However, important effects of oestrogen on liver physiology can also be mediated by its effects on the hypothalamic-pituitary-gonadal axis, which controls hormone secretion 101, 102 . In rodents, hypophysectomy abolishes sex-dependent differences in HCC 103 . Oestrogen in females can modulate GH signalling by promoting more-frequent pulses of lower amplitude GH secretion, as compared with males 104 . In turn, GH targets the liver, inducing a sex-specific pattern of gene expression, which is particularly evident in rodents at puberty but is also found in adult humans 105 . The influence of GH on transcription is mediated by the activation of signal transducer and activator of transcription 5 (STAT5) through phosphorylation 106 . Activated STAT5 can protect hepatocytes from chronic injuries and malignant transformation 13 , providing another possible mechanism for sexual dimorphism in HCC development.
The lesser susceptibility of women to HCC can also result from oestrogenstimulated secretion of PRL by the pituitary gland 11, 12 . In this context, PRL may protect females from liver tumorigenesis by restricting the basal level of innate immune inflammatory signalling in hepatocytes, which may be upregulated in case of cellular that may contribute to the sex-specific regulation of immune-related genes 85, 86 . In one study of an autoimmune disease, systemic lupus erythematosus (SLE), several X-linked mi RNAs were found to be overexpressed in T cells of female patients compared with those of male patients 87 . Several of the differentially expressed mi RNAs are located within 5,000 base pairs of an oestrogen response element, and one predicted target of these mi RNAs was the E3 ubiquitin ligase CBL, a myelomonocytic leukaemia proto-oncogene and a negative regulator of T cell receptor (TCR) activity. The downregulation of CBL in T cells of patients with SLE was suggested to alter TCR signalling, potentially contributing to the development of the autoimmunity 87 . Overall, a complex picture emerges whereby sexual dimorphism in the immune system is the combined result of multiple determinants 68 . Irrespective of the detailed mechanisms, which can affect key cell populations such as T Reg cells in a complex manner, the greater susceptibility of women to autoimmune diseases is likely to be accompanied by enhanced immune surveillance against various tumour types. As discussed below, further insights into this topic will probably lead to improved forms of cancer immunotherapy and prevention.
Metabolism. Steroid hormones are also central regulators of systemic metabolism, acting at several levels 88 . Both ERs and ARs increase glucose tolerance and restrain visceral fat accumulation 89 . Reduced ERα signalling in postmenopausal women and people with an aromatase deficiency, who have compromised conversion of androgens to oestrogens, is associated with increased adiposity 88 , a known risk factor for cancer development 90 . Cancer is often associated with a severe body-wasting syndrome called cachexia 91 . Cachexia is associated with reduced survival and is a sexually dimorphic trait that is more prominent in males 92 . Such a wasting syndrome promotes not only a decrease in skeletal muscle mass but also cardiac atrophy, a phenomenon more pronounced in the hearts of males owing to an increased autophagic response 93 . The majority of males with cancer aged 60-69 years old experiences sarcopenia -a condition characterized by the loss of muscle mass and strength, linked to a reduction in testosterone -which is a positive regulator of muscle trophism 94 . A decrease in androgen levels has been noticed in multiple studies in males with cancer 95 , which may be a result of chemotherapy 96 . 11 , a known risk factor for HCC development 107 . More specifically, PRL stimulation of hepatic cell lines suppressed their response to IL-1 receptor (IL-1R), Toll-like receptor 4 (TLR4) and tumour necrosis factor receptor 1 (TNFR1; also known as TNFRSF1A) signalling by degradation of adaptor proteins such as TNF receptor-associated factor 6 (TRAF6), thereby suppressing MYC activation and proliferation 11 . Several other cancer types exhibit higher incidence and aggressive behaviour in males and postmenopausal females compared with premenopausal females, with similar gender differences occurring in corresponding animal models. These include colon cancer, gliomas, melanoma and non-melanoma skin cancer, head and neck squamous cell carcinoma (HNSCC), oesophageal cancer and NSCLC. Protection in women extends to haematological malignancies, especially lymphomas, even after menopause -suggesting that a non-sex-hormone mechanism is also involved 1, 2 . In many cases, higher oestrogen signalling, leading to ERβ activation, has been implicated as the likely explanation (males were not tested) 112 . ERβ function is required for normal lung and colon morphogenesis, ensuring the formation of a correct tissue architecture 25, 26 , and its activation is beneficial in experimental models of colon cancer 113 as well as glioma 114 , mesothelioma 115 , renal cell carcinoma (RCC) 108 and T cell lymphoma 116 . In contrast to the above tumour types, the incidence of thyroid cancer is significantly higher in females than in males 3 . Even though several studies tried to find associations between this neoplasm and hormonal or dietary factors, the reasons for this discrepancy are still unclear 3 . However, experimentally, it should be noted that AR expression in thyroid follicular cells was reported to reduce proliferation 117 , whereas oestrogen treatment induced proliferation and suppressed apoptosis 118 , suggesting possibly opposite roles of sex hormones in this context.
Sex chromosomes and oncogenesis
The most substantial genetic differences between the two sexes reside in the X and Y chromosomes. Mutations and/or epigenetic deregulation of genes on sex chromosomes could contribute to oncogenesis. Deregulated expression of both protein-encoding genes and non-coding RNAs is likely to be involved, with a probable interplay with sex hormone action, especially given that the AR is X-linked (FIG. 4) . X chromosome. To counteract differences in X chromosome gene dosage, mammals use the X-inactivation process, which involves transcriptional silencing (through DNA methylation) and chromatin compaction promoted by the long non-coding RNA (lncRNA) X-inactive specific transcript (XIST) 119, 120 . Female tissues are mosaic for most X-linked genes, resulting from X inactivation in every cell. Although inactivation of one X chromosome over the other is generally random, preferential inactivation of one chromosome (skewed X-inactivation) can protect women against the consequences of X-linked gene mutations 121 . On the contrary, the absence of X inactivation can have detrimental effects: for instance, loss of XIST has been reported in breast, ovarian and cervical cancer cell lines 122, 123 , and, in female mice only, it caused deregulation of haematopoietic lineages and genome-wide changes in gene expression, leading to the emergence of myeloid neoplasms 124 .
for this protection. ERβ levels are often diminished in these various cancer types, and sustained ERβ expression is a favourable prognostic marker 108 . In colon cancer, a polymorphism in the promoter of the gene encoding ERβ, which possibly influences its activity levels, has been associated with increased patient survival 109 . Polymorphisms have also been identified in the gene encoding epidermal growth factor receptor (EGFR), and these have a positive association with colon cancer survival in women and a negative association in men 110 , pointing to the possibility that interplay between EGFR and ERβ signalling underlies the differences between the two sexes.
In skin squamous cell carcinoma and HNSCC cells in which ERβ expression is down-modulated, increased ERβ expression and/or agonist-specific stimulation promotes differentiation through induction of NOTCH1 transcription and function 20 . Also in melanoma, ERβ expression levels are inversely related to primary cancer progression in both men and women 111 , and, in a mouse model of the disease, treatment with tamoxifen -which may also function as an ERβ agonist -significantly inhibited metastatic spread in female animals In other settings, cancer development has been linked to increased rather than decreased XIST expression. XIST expression can be upregulated in glioblastoma cells of both sexes, and its knockdown results in tumour suppression 125 . In testicular tumours, increased XIST expression that is not coupled with the methylation of X-linked genes is also frequently observed, indicating that its role may be distinct from this process 126 . There are regions of the X chromosome that escape XIST-dependent inactivation. Besides the pseudoautosomal regions, which have corresponding regions of homology on the Y chromosome, other single genes escaping inactivation are spread throughout the chromosome. In particular, UTX (also known as KDM6A) encodes a histone H3 lysine 27 (H3K27) demethylase that is expressed by both X chromosomes 127 . In men, UTX has a homologue on the Y chromosome, called UTY (also known as KDM6C), the catalytic activity of which is very low or absent 128 . UTX has a tumour-suppressing function, and inactivating mutations in this gene are not compensated by UTY (FIG. 4) . This seems to be of importance in human T-ALL, a childhood tumour more common in males than in females, and in a corresponding experimental model of this disease [129] [130] [131] . Additional X-linked genes altered in T-ALL are PHD finger protein 6 (PHF6) and ribosomal protein L10 (RPL10), which are mutated almost exclusively in male patients 132, 133 . Loss-of-function UTX mutations have also been found in RCC and oesophageal squamous cell carcinoma, and lysine demethylase 5C (KDM5C), the truncating mutations of which are found in RCC cells and trigger genomic instability 141 (see Supplementary information S1 (table)).
As mentioned, FOXP3 is an X-linked gene that plays an important part in the immune system by controlling transcription in T Reg cells. Expression of this gene has also been observed in different types of tumour cells, such as melanoma cells 142 and those of the lung 142 , colon 142 and pancreas 143 , which, similar to T Reg cells, can mediate FOXP3-dependent immune suppression. Furthermore, in both breast and prostate cancer, FOXP3 has been proposed to exert a tumour-suppressing function though inhibition of nuclear factor-κB (NF-κB) activation, through a FOXP3-miR-146-NF-κB axis 144, 145 . We further note that a specific member of the SRY-box (SOX) family of transcription factors, SOX3, is encoded in the X chromosome (FIG. 4) . This is discussed below in the context of the Y-encoded SRY gene.
The X chromosome is also highly enriched in mi RNAs, with a density almost twofold higher than in the autosomes (see Supplementary information S1 (table)). Among these are several mi RNAs with pro-oncogenic functions (such as miR-222 and miR-223 in gastric cancer 146, 147 ) and others with potential positive prognostic significance (such as miR-20b and miR-361 for oropharyngeal carcinoma) 148 .
There is also a cluster of several miRNAs (miR-506, miR-507, miR-508, miR-513a-1, miR-513a-2, miR-513b and miR-513c) that might fine-tune the response of cells to PI3K-AKT signalling 149 . Although all of these mi RNAs map to the X chromosome, whether or not their differential expression contributes to gender differences in cancer risk remains to be established. ). Importantly, loss of the entire Y chromosome also occurs in normal tissues -it is frequently observed in normal haematopoietic cells of elderly men 157 and is also induced by smoking 158 . Loss of the entire Y chromosome in blood cancers that are more frequent in men than in women 134, 135 . Group 4 medulloblastoma is the most common subgroup of medulloblastoma, with an intermediate prognosis during childhood that worsens in the case of adult patients 136 . Group 4 medulloblastomas are also more prevalent in males, and it is noteworthy that, besides UTX, several other mutated oncogenes and tumour-suppressor genes in these tumours are located on the X chromosome 136 (see Supplementary information S1 (table)). These include the genes for a component of histone-deacetylase complexes, zinc finger MYM-type protein 3 (ZMYM3), and the ATP-dependent RNA helicase DDX3X, which has a homologue on the Y chromosome that is not translated. ZMYM3 is mutated exclusively in the tumours of male patients, whereas DDX3X is also mutated in the tumours of females, in the allele that escapes X inactivation 137 .
Loss-of-function mutations in DDX3X
are also observed at a higher frequency in males with natural killer/T cell lymphoma (NKTCL) than in females with this disease 138 . NKTCL is more prevalent in males; however, whether DDX3X loss is responsible for this gender bias is still not understood. Downregulation of DDX3X is also observed in NSCLC, wherein the absence of the helicase promotes malignancy and is associated with poor survival 139 
.
Other tumour-suppressor genes mapping to the X chromosome include APC membrane recruitment protein 1 (AMER1, also known as WTX), which is involved in the pediatric kidney cancer Wilms tumour 160 . Chromosomal amplifications of the pseudoautosomal region Y11p2 (adjacent to SRY, which is located at Y11p3) have been found in male patients with HCC 161 , possibly contributing to the higher incidence of HCC in males. Indeed, SRY ablation can impair the development of HCC 162 and decrease chemoresistance 161 (FIG. 3) . SRY encodes a high-mobility group (HMG) box transcription factor of the SOX family. SRY shares a substantial amount of homology with SOX1, SOX2 and SOX3, and may have evolved from these 163 . Similar to SOX2 (REF. 164 ), SRY is likely to play a part in cancer stem cell self-renewal, as suggested by its control of the expression of OCT4 (also known as POU5F1) (FIG. 4) , another key cellreprogramming and stem cell factor 161 , and of a MYC co-activator, SAGA-associated factor 29 (SGF29) 162 . Interestingly, together with these growth-promoting functions, SRY has also been reported to negatively regulate AR transcriptional activity on other genes through an as-yet-unknown mechanism 165 . TSPY is another Y-linked gene, coding for a SET proto-oncogene and nucleosome assembly protein, with a known function in male germ-cell differentiation, mitosis and meiosis 166 . Increased TSPY expression occurs in testicular germ-cell tumours 166 as well as other types of cancer (including prostate cancer 167 ) and HCC from male patients 168 . Interestingly, although TSPY seems to be pro-oncogenic, it has a homologue on the X chromosome, TSPX (also known as TSPYL2), which can be tumour suppressive 169 and protects from HBV infection 170 . In fact, both ectopic TSPY activation and TSPX silencing can contribute to the initiation and progression of HCC, which, as noted above, is a male-predominant cancer 168 (FIG. 3) . In these tumours, TSPY also promotes AR expression 171 . Conversely, at least in prostate cancer cells, AR stimulation by androgen leads to TSPY upregulation 172 . information can impinge on the cancer cells themselves as well as the surrounding stromal environment that, as discussed, can have not only a cancer-promoting but also a cancer-initiating function (FIG. 5) .
As for the tumour cells themselves, important molecular insights can be provided by recent developments in large-scale genome sequencing of tumours coupled with epigenetic, transcriptomic and proteomic analysis and associated clinical information. For instance, analysis of The Cancer Genome Atlas database showed differences in the mutational landscape of HNSCC in the male versus female populations, with each sex having distinct gene expression profiles 20 . It will be interesting to assess whether similar differences between sexes apply to other cancer types, possibly in a cell typeor cancer subtype-specific manner, and to determine whether subsets of cancer patients with mutational and/or gene expression profiles closer to those of the other sex can be identified; such patients might have cancers with similar clinical behaviours to those of the opposite sex.
At the level of the cancer stroma and organ homeostasis, the regulation of angiogenesis and inflammation by sex hormones stands out as a key element of divergent cancer progression between the two sexes. Systemically, we believe that the most promising area in which understanding sex bias can be of value is at the level of the immune system. Immunotherapy based on immune checkpoint inhibitors is rapidly emerging as a key therapeutic mainstay of cancer types with high gene mutation frequencies 182 , such as NSCLC Finally, RBMY (an RNA-binding motif gene on the Y chromosome; also known as RBMY1A1) encodes a male germ-cell-specific regulator of RNA splicing involved in spermatogenesis. RBMY is aberrantly activated in male HCC 173 , in which similar to TSPY, it can enhance AR expression and activity as well as cancer development 174 (FIG. 3) .
Conclusions and future perspectives Sex-specific differences in cancer incidence and mortality across ethnic backgrounds point to substantial influences of gender on both cancer initiation and progression (FIG. 1) . An important notion is that cancer as a disease is not limited to a group of genetically deranged cells and their immediate environment but is also linked to general alterations in organ homeostasis as a result of perturbed developmental and/or morphogenetic signals and systemic factors 64, 175 . Selection of cells with cumulative somatic mutations 176 and a 'big bang' expansion of single cell populations with pre-existing dominant alterations 177 have both been implicated in cancer development. However, there can be clonal expansion of cells harbouring many cancer driver mutations without any clinical signs of the disease 178 . Indeed, in most cases, pre-malignant lesions do not progress into malignancy for reasons that are poorly understood 179, 180 . This observation led to the view of an 'ecological cellular environment' that has a key role in restraining or unleashing tumour growth 180, 181 . As discussed throughout this article, sex hormones and sex chromosome-encoded A complex interplay exists between sex hormones and the X and Y chromosomes, with epigenetic control of gene expression as one link. These combined factors can differentially affect cancer development at multiple levels: first, the cancer cells of origin, through modulation of ubiquitous or cancer-typespecific intracellular processes; second, the cancer stroma and surrounding 'field cancerization' of tissues, through angiogenesis and inflammation; and, third, systemically, through alterations of the immune system and metabolism. It can be further proposed that using drugs to target sex hormone action and associated epigenetic control mechanisms can have beneficial effects for multiple cancer types, well beyond those of reproductive organs. and melanoma, which exhibit a more aggressive behaviour in the male than female populations 6, 183 . As we discussed, modulation of the immune system by sex hormones can be involved in this sexual dimorphism, as well as X-linked expression of cytokine genes and immune-modulatory mi RNAs. It will be important to assess to what extent these elements have an effect on key immune checkpoints, such as the programmed cell death protein 1 (PD1)-PD1 ligand 1 (PDL1) axis, which acts on various T cell populations, neighbouring immuno modulatory cells and cancer cells themselves.
Sexual dimorphisms that favour females are also observed in lifespan and ageing 184 . Such differences are once again defined by multiple elements. Sex hormones, especially oestrogens, can play an important part in the control of cellular senescence and ageing-associated tissue deteriorations 36, 185 . Concomitantly, at the chromosomal level, it has been suggested that X-linked mutations are more likely to exert detrimental effects in male cells than in female cells, which have the advantageous possibility of selective inactivation of the X chromosome that carries a mutation 121 . Detailed knowledge of the effect of sex hormones on cancer development in organs of non-reproductive function has translational importance, given the available pharmacological tools to either enhance or suppress their function. This is especially true for steroid hormones 186, 187 . Along these lines, a topic of great interest and translational potential is that of the interplay between steroid hormones and epigenetic reprogramming of cells, such as the well-known interplay between ER and AR function and key histone-and DNA-modifying enzymes 14 , which can be targeted by a large battery of natural and synthetic compounds 188 . Interventions at this level are of great promise for both cancer prevention and treatment.
